{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:44:17Z","timestamp":1782729857902,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA030460"],"award-info":[{"award-number":["R01AA030460"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["P01AA029541"],"award-info":[{"award-number":["P01AA029541"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09813-1","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:07Z","timestamp":1780466707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gabapentin to achieve HIV viral load suppression in people with risky drinking in Mbarara, Uganda: study protocol for a randomized, double-blinded, placebo-controlled trial (GRAIL)"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-9209","authenticated-orcid":false,"given":"Ve","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kekibiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie R.","family":"Muyindike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gnatienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneka I.","family":"Emenyonu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bullard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Lunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"9813_CR1","unstructured":"World Health Organization. HIV Country Profiles 2022. HIV Country Intelligence. https:\/\/cfs.hivci.org\/. Accessed 29 Sep 2023."},{"key":"9813_CR2","unstructured":"UNAIDS. Fast-Track\u2014Ending the AIDS epidemic by 2030. 2014. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/201506_JC2743_Understanding_FastTrack_en.pdf. Accessed 30\u00a0Dec 2022."},{"issue":"2","key":"9813_CR3","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i2.15s","volume":"22","author":"N Mbona Tumwesigye","year":"2022","unstructured":"Mbona Tumwesigye N, Ocama P, Basangwa D, et al. Drugs and alcohol use patterns among those seeking care in urban rehabilitation centres before and during early months of COVID-19 in Uganda. Afr Health Sci. 2022;22(2):15S. https:\/\/doi.org\/10.4314\/ahs.v22i2.15s.","journal-title":"Afr Health Sci"},{"key":"9813_CR4","unstructured":"Alcohol, drinkers only per capita (15+ years) consumption in litres of pure alcohol, three-year average. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/alcohol-drinkers-only-per-capita-(15-)consumption-in-litres-of-pure-alcohol. Accessed 26\u00a0Jan 2026."},{"key":"9813_CR5","unstructured":"World health statistics 2023: monitoring health for the SDGs, sustainable development goals. https:\/\/www.who.int\/publications\/i\/item\/9789240074323. Accessed 26 Jan 2026."},{"key":"9813_CR6","unstructured":"Uganda: New WHO Data Reveal Worryingly High Levels of Alcohol Use - Movendi International. https:\/\/movendi.ngo\/news\/2023\/05\/27\/uganda-new-who-data-reveal-worryingly-high-levels-of-alcohol-use\/. Accessed 1 Nov 2023."},{"key":"9813_CR7","unstructured":"World Health Organization. Alcohol, total per capita (15+) consumption (in litres of pure alcohol). 2020. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/total-(recorded-unrecorded)-alcohol-per-capita-(15-)-consumption. Accessed 3 Nov 2021."},{"issue":"6","key":"9813_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s10461-019-02716-0","volume":"24","author":"J Velloza","year":"2020","unstructured":"Velloza J, Kemp CG, Aunon FM, Ramaiya MK, Creegan E, Simoni JM. Alcohol use and antiretroviral therapy non-adherence among adults living with HIV\/AIDS in Sub-Saharan Africa: a systematic review and meta-analysis. AIDS Behav. 2020;24(6):1727\u201342. https:\/\/doi.org\/10.1007\/s10461-019-02716-0.","journal-title":"AIDS Behav"},{"issue":"3","key":"9813_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/QAD.0000000000002427","volume":"34","author":"SB Puryear","year":"2020","unstructured":"Puryear SB, Balzer LB, Ayieko J, et al. Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. AIDS. 2020;34(3):405\u201313. https:\/\/doi.org\/10.1097\/QAD.0000000000002427.","journal-title":"AIDS"},{"issue":"9","key":"9813_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/add.14655","volume":"114","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114(9):1547\u201355. https:\/\/doi.org\/10.1111\/add.14655.","journal-title":"Addiction"},{"issue":"1","key":"9813_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","volume":"174","author":"BJ Mason","year":"2014","unstructured":"Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2013.11950.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"9813_CR12","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19r02465","volume":"21","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Stanciu CN, Kotapati PV, et al. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. Prim Care Companion CNS Disord. 2019;21(4):19r02465. https:\/\/doi.org\/10.4088\/PCC.19r02465.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"4","key":"9813_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.46747\/cfp.6704269","volume":"67","author":"J Weresch","year":"2021","unstructured":"Weresch J, Kirkwood J, Korownyk CS. Gabapentin for alcohol use disorder. Can Fam Physician. 2021;67(4):269. https:\/\/doi.org\/10.46747\/cfp.6704269.","journal-title":"Can Fam Physician"},{"issue":"6","key":"9813_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","volume":"2020","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;(6):CD007938. https:\/\/doi.org\/10.1002\/14651858.CD007938.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"9813_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180(5):728\u201336. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0249.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"9813_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11606-008-0594-0","volume":"23","author":"D Frank","year":"2008","unstructured":"Frank D, DeBenedetti AF, Volk RJ, Williams EC, Kivlahan DR, Bradley KA. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race\/ethnic groups. J Gen Intern Med. 2008;23(6):781\u20137. https:\/\/doi.org\/10.1007\/s11606-008-0594-0.","journal-title":"J Gen Intern Med"},{"issue":"16","key":"9813_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789\u201395. https:\/\/doi.org\/10.1001\/archinte.158.16.1789.","journal-title":"Arch Intern Med"},{"issue":"7","key":"9813_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","volume":"31","author":"KA Bradley","year":"2007","unstructured":"Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208\u201317. https:\/\/doi.org\/10.1111\/j.1530-0277.2007.00403.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"9813_CR19","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s10461-022-03597-6","volume":"26","author":"KC Alcover","year":"2022","unstructured":"Alcover KC, Emenyonu NI, Fatch R, et al. Concordance between point-of-care urine Ethyl Glucuronide alcohol tests and self-reported alcohol use in persons with HIV in Uganda. AIDS Behav. 2022;26(8):2539\u201347. https:\/\/doi.org\/10.1007\/s10461-022-03597-6.","journal-title":"AIDS Behav"},{"issue":"12","key":"9813_CR20","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/jn\/nxz146","volume":"149","author":"IAT van de Luitgaarden","year":"2019","unstructured":"van de Luitgaarden IAT, Beulens JWJ, Schrieks IC, et al. Urinary Ethyl Glucuronide can be used as a biomarker of habitual alcohol consumption in the general population. J Nutr. 2019;149(12):2199\u2013205. https:\/\/doi.org\/10.1093\/jn\/nxz146.","journal-title":"J Nutr"},{"key":"9813_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/JEP.S124391","volume":"9","author":"GC Quintero","year":"2017","unstructured":"Quintero GC. Review about gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol. 2017;9:13\u201321. https:\/\/doi.org\/10.2147\/JEP.S124391.","journal-title":"J Exp Pharmacol"},{"key":"9813_CR22","unstructured":"National Institute on Alcohol Abuse and Alcoholism. A Pocket Guide for Alcohol Screening and Brief Intervention. 2005. https:\/\/pubs.niaaa.nih.gov\/publications\/Practitioner\/pocketguide\/pocket_guide.htm. Accessed 4\u00a0Oct 2021."},{"issue":"11","key":"9813_CR23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4088\/jcp.v68n1108","volume":"68","author":"FA Furieri","year":"2007","unstructured":"Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691\u2013700. https:\/\/doi.org\/10.4088\/jcp.v68n1108.","journal-title":"J Clin Psychiatry"},{"key":"9813_CR24","doi-asserted-by":"publisher","unstructured":"McLellan AT, Luborsky L, Cacciola J. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis. 1985;173(7):412\u201323. https:\/\/doi.org\/10.1097\/00005053-198507000-00005.","DOI":"10.1097\/00005053-198507000-00005"},{"key":"9813_CR25","doi-asserted-by":"publisher","unstructured":"Chesney M, Ickovics JR, Chambers DB, et al. Self-Reported Adherence to Antiretroviral Medications among Participants in HIV Clinical Trials: The AACTG Adherence Instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS care. 2000;12:255\u2013266. https:\/\/doi.org\/10.1080\/09540120050042891.","DOI":"10.1080\/09540120050042891"},{"issue":"2","key":"9813_CR26","doi-asserted-by":"publisher","DOI":"10.7895\/ijadr.v5i2.222","volume":"5","author":"TF Babor","year":"2016","unstructured":"Babor TF, Robaina K. The Alcohol Use Disorders Identification Test (AUDIT): a review of graded severity algorithms and national adaptations. Int J Alcohol Drug Res. 2016;5(2):2. https:\/\/doi.org\/10.7895\/ijadr.v5i2.222.","journal-title":"Int J Alcohol Drug Res"},{"key":"9813_CR27","volume-title":"Alcohol Timeline Followback (TLFB) Users\u2019 Manual","author":"L Sobell","year":"1995","unstructured":"Sobell L, Sobell M. Alcohol Timeline Followback (TLFB) Users\u2019 Manual. Alcohol Research Foundation; 1995."},{"issue":"8","key":"9813_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289\u201395.","journal-title":"Alcohol Clin Exp Res"},{"key":"9813_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1037\/10248-014","volume-title":"Assessing Drinkers\u2019 Motivation for Change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)","author":"WR Miller","year":"1997","unstructured":"Miller WR, Tonigan JS. Assessing Drinkers\u2019 Motivation for Change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). American Psychological Association; 1997. p. 369. https:\/\/doi.org\/10.1037\/10248-014."},{"issue":"9","key":"9813_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr\u00f6m KO. The Fagerstr\u00f6m Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119\u201327. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01879.x.","journal-title":"Br J Addict"},{"key":"9813_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1178-x","volume":"17","author":"EC Baron","year":"2017","unstructured":"Baron EC, Davies T, Lund C. Validation of the 10-item Centre for Epidemiological Studies Depression Scale (CES-D-10) in Zulu, Xhosa and Afrikaans populations in South Africa. BMC Psychiatry. 2017;17:6. https:\/\/doi.org\/10.1186\/s12888-016-1178-x.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"9813_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing Generalized Anxiety Disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"issue":"0 1","key":"9813_CR33","doi-asserted-by":"publisher","first-page":"E237","DOI":"10.1111\/j.1530-0277.2012.01887.x","volume":"37","author":"JE Glass","year":"2013","unstructured":"Glass JE, Kristjansson SD, Bucholz KK. Perceived alcohol stigma: factor structure and construct validation. Alcohol Clin Exp Res. 2013;37(0 1):E237\u201346. https:\/\/doi.org\/10.1111\/j.1530-0277.2012.01887.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"9813_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jadohealth.2006.08.001","volume":"40","author":"K Wright","year":"2007","unstructured":"Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV + youth. J Adolesc Health. 2007;40(1):96\u20138. https:\/\/doi.org\/10.1016\/j.jadohealth.2006.08.001.","journal-title":"J Adolesc Health"},{"issue":"Suppl 1","key":"9813_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10461-021-03414-6","volume":"26","author":"L Beer","year":"2022","unstructured":"Beer L, Tie Y, McCree DH, et al. HIV stigma among a national probability sample of adults with diagnosed HIV-United States, 2018-2019. AIDS Behav. 2022;26(Suppl 1):39\u201350. https:\/\/doi.org\/10.1007\/s10461-021-03414-6.","journal-title":"AIDS Behav"},{"issue":"6","key":"9813_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/nur.10011","volume":"24","author":"BE Berger","year":"2001","unstructured":"Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV Stigma Scale. Res Nurs Health. 2001;24(6):518\u201329. https:\/\/doi.org\/10.1002\/nur.10011.","journal-title":"Res Nurs Health"},{"issue":"6","key":"9813_CR37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/archinte.158.6.626","volume":"158","author":"LE Kazis","year":"1998","unstructured":"Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158(6):626\u201332. https:\/\/doi.org\/10.1001\/archinte.158.6.626.","journal-title":"Arch Intern Med"},{"issue":"1","key":"9813_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jphys.2015.07.001","volume":"62","author":"N Poquet","year":"2016","unstructured":"Poquet N, Lin C. The Brief Pain Inventory (BPI). J Physiother. 2016;62(1):52. https:\/\/doi.org\/10.1016\/j.jphys.2015.07.001.","journal-title":"J Physiother"},{"issue":"4","key":"9813_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1023\/a:1005132430171","volume":"28","author":"JA Fleishman","year":"2000","unstructured":"Fleishman JA, Sherbourne CD, Crystal S, et al. Coping, conflictual social interactions, social support, and mood among HIV-infected persons. HCSUS Consortium. Am J Community Psychol. 2000;28(4):421\u201353. https:\/\/doi.org\/10.1023\/a:1005132430171.","journal-title":"Am J Community Psychol"},{"key":"9813_CR40","doi-asserted-by":"publisher","unstructured":"Kazis LE, Miller DR, Clark JA, Skinner KM, Lee A, Ren XS, Spiro A 3rd, Rogers WH, Ware JE Jr. Improving the response choices on the veterans SF-36 health survey role functioning scales: results from the Veterans Health Study. J Ambul Care Manage. 2004;27(3):263-80. https:\/\/doi.org\/10.1097\/00004479-200407000-00010.","DOI":"10.1097\/00004479-200407000-00010"},{"issue":"1-3","key":"9813_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","volume":"118","author":"MK Vernon","year":"2010","unstructured":"Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118(1\u20133):271\u20138. https:\/\/doi.org\/10.1016\/j.schres.2010.01.021.","journal-title":"Schizophr Res"},{"issue":"11","key":"9813_CR42","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.3390\/ijms131114788","volume":"13","author":"G Viel","year":"2012","unstructured":"Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci. 2012;13(11):14788\u2013812. https:\/\/doi.org\/10.3390\/ijms131114788.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9813_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25129","volume":"5","author":"HA Tindle","year":"2022","unstructured":"Tindle HA, Freiberg MS, Cheng DM, et al. Effectiveness of Varenicline and Cytisine for alcohol use reduction among people with HIV and substance use: a randomized clinical trial. JAMA Netw Open. 2022;5(8):e2225129. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25129.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"9813_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297948","volume":"19","author":"JI Tsui","year":"2024","unstructured":"Tsui JI, Rossi SL, Cheng DM, et al. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLoS One. 2024;19(2):e0297948. https:\/\/doi.org\/10.1371\/journal.pone.0297948.","journal-title":"PLoS One"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09813-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:47:26Z","timestamp":1782726446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09813-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9813"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09813-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6856284\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GRAIL study was approved by the Institutional Review Boards of Boston University Medical Campus (H-42904), Mbarara University of Science and Technology Research Ethics Committee (MUST-2022-668) and the Uganda National Council for Science and Technology (HS2622ES). The study was also approved by the Uganda\u2019s National Drug Authority. All study participants will complete the informed consent process and provide their consent in writing or use their fingerprint in cases where writing may not be feasible.The IRBs and Council will be informed of any substantial modifications and deviations. Participants will be informed of any modifications that may have an impact on them and further permissions and consents will be requested if needed. ClinicalTrials.gov records will be updated accordingly. The funder will be notified of any deviations through the progress report, submitted every 6\u00a0months.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"Not applicable, personal and clinical details of participants will not be provided in the reporting of trial results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}